Filing Details
- Accession Number:
- 0001739614-23-000012
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-02 19:26:57
- Reporting Period:
- 2023-02-01
- Accepted Time:
- 2023-02-02 19:26:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1739614 | Inhibrx Inc. | INBX | Biological Products, (No Disgnostic Substances) (2836) | 824257312 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1766433 | P. Brendan Eckelman | C/O Inhibrx, Inc. 11025 North Torrey Pines Road, Suite 200 La Jolla CA 92037 | Chief Scientific Officer | No | Yes | No | No |
| 1821294 | Eckelman Living Trust Dated February 5, 2014 | C/O Inhibrx, Inc. 11025 North Torrey Pines Road, Suite 200 La Jolla CA 92037 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-01 | 13,449 | $24.29 | 2,102,104 | No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| Common Stock | Disposition | 2023-02-01 | 14,608 | $25.08 | 2,087,496 | No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| Common Stock | Disposition | 2023-02-01 | 693 | $25.66 | 2,086,803 | No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| Common Stock | Disposition | 2023-02-02 | 10,120 | $25.40 | 2,076,683 | No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| Common Stock | Disposition | 2023-02-02 | 1,130 | $25.89 | 2,075,553 | No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
| No | 4 | S | Indirect | By the Eckelman Living Trust dated February 5, 2014 |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 160,000 | Indirect | By trust |
| Common Stock | 160,000 | Indirect | By trust |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014.
- The shares were sold in multiple transactions at prices ranging from $23.59 to $24.58, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.
- The shares were sold in multiple transactions at prices ranging from $24.62 to $25.61, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- The shares were sold in multiple transactions at prices ranging from $25.63 to $25.70, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- The shares were sold in multiple transactions at prices ranging from $24.85 to $25.82, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- The shares were sold in multiple transactions at prices ranging from $25.85 to $25.99, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
- These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
Billionaire Hedge Funds
